Antibiotice Iasi | Romania Feed

Pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) ended 2023 with net profit of RON80.7 million, up 109.5% from 2022, and a turnover of RON600.8 million, up 7.2% on the year, in line with calculations by Ziarul Financiar (ZF) daily based on data from the company's annual preliminary financial report published at the Bucharest Stock Exchange.

Antibiotice Iasi (ATB.RO), the largest Romanian-held drug maker, on Friday reported on the Bucharest Stock Exchange that regional investment fund SIF Oltenia (SIF5) bought 18 million of its shares, for RON0.59 per unit, on August 25, 2021 .

Antibiotice Iasi (ATB.RO), the largest Romanian-held pharmaceutical producer, on Wednesday reported sales of RON66.1 million for the first quarter of 2021, down 10.2% on the year, and a net profit of RON4.03 million, which is close to the level reported in the same period in 2020.

Romanian state-owned Antibiotice Iasi (ATB.RO), the largest pharmaceutical producer in Romania, said in a stock market report on Wednesday that regional investment fund SIF Oltenia (SIF5.RO) reached the 23.07% threshold of Antibiotice Iasi’s share capital following a transaction held on April 12, 2021.

Antibiotice Iasi (ATB.RO), the largest pharmaceutical producer in Romania, has won a tender held by the European Commission to supply necessary stock for the second wave of the Covid pandemic.